Cargando…

Effective Tacrolimus Treatment for Patients with Non-Severe Aplastic Anemia That is Refractory/Intolerant to Cyclosporine A: A Retrospective Study

BACKGROUND: For symptomatic non-severe aplastic anemia (NSAA) patients who cannot afford anti-thymocyte globulin (ATG) or allogeneic hematopoietic stem cell transplantation (HSCT), tacrolimus (FK) may be an option if these patients do not respond or become tolerant to cyclosporine A (CsA). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Yali, Huang, Yuzhou, Zhou, Wenzhe, Liu, Xinjian, Chen, Fangfei, Yang, Chen, Chen, Miao, Ruan, Jing, Han, Bing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779311/ https://www.ncbi.nlm.nih.gov/pubmed/33408460 http://dx.doi.org/10.2147/DDDT.S275975

Ejemplares similares

Effective treatment of aplastic anemia secondary to chemoradiotherapy using cyclosporine A
por: Ruan, Jing, et al.
Publicado: (2021)

Adding cyclosporin A to eltrombopag for aplastic anemia secondary to chemotherapy for solid cancers
por: Wan, Ziqi, et al.
Publicado: (2023)

Cyclosporine Monotherapy in Pediatric Patients With Non-severe Aplastic Anemia: A Retrospective Analysis
por: Li, Hongmin, et al.
Publicado: (2022)

Eltrombopag with or without Tacrolimus for relapsed/refractory acquired aplastic anaemia: a prospective randomized trial
por: Ji, Jiang, et al.
Publicado: (2023)

Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial
por: Wan, Ziqi, et al.
Publicado: (2023)

P784: CYCLOSPORINE WITH THROMBOPOIETIN RECEPTOR AGONIST IN THE TREATMENT OF APLASTIC ANEMIA WITH OR WITHOUT ANTI-THYMOCYTE IMMUNOGLOBULIN：A MULTICENTER REAL WORLD RETROSPECTIVE STUDY
por: Chen, Miao, et al.
Publicado: (2023)

Cyclosporine monotherapy for severe aplastic anemia: a developing country experience
por: Al-Ghazaly, Jameel, et al.
Publicado: (2005)

Cyclosporine Therapy in Patients with Transfusion-independent Non-severe Aplastic Anemia: A Retrospective Analysis
por: Matsuda, Kensuke, et al.
Publicado: (2018)

Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China
por: Zhang, Zhuxin, et al.
Publicado: (2023)

Population Pharmacokinetics of Cyclosporine in Chinese Pediatric Patients With Acquired Aplastic Anemia
por: Gao, Xuan, et al.
Publicado: (2022)

Correlation of the Plasma Concentration of Eltrombopag With Efficacy in the Treatment of Refractory Aplastic Anemia: A Single-Centre Study in China
por: Zuo, Wei, et al.
Publicado: (2020)

P792: CLINICAL STUDY OF HETROMBOPAG COMBINED WITH CYCLOSPORINE A IN THE TREATMENT OF CHILDREN WITH NON-SEVERE APLASTIC ANEMIA
por: Chang, Lixian, et al.
Publicado: (2023)

A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy
por: Peng, Guangxin, et al.
Publicado: (2022)

Immunomodulation Therapy for Severe Aplastic Anemia: —ALG Versus ALG Plus Cyclosporin A—
por: Park, Chong Won, et al.
Publicado: (1989)

Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia
por: Li, Ning, et al.
Publicado: (2012)

Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia
por: Chang, Hong, et al.
Publicado: (2023)

PB2041: COMPARISON OF ELTROMBOPAG AND AVATROMBOPAG IN THE TREATMENT OF REFRACTORY/RELAPSED APLASTIC ANEMIA, A SINGLE CENTER STUDY IN CHINA
por: Zhang, Zhuxin, et al.
Publicado: (2023)

Successful Treatment of Methimazole-Induced Severe Aplastic Anemia by Granulocyte Colony-Stimulating Factor, Methylprednisolone, and Cyclosporin
por: Honda, Munehiro
Publicado: (2011)

Mass cytometry analysis identifies T cell immune signature of aplastic anemia and predicts the response to cyclosporine
por: Zhang, Lele, et al.
Publicado: (2023)

Hereditary intrinsic factor deficiency in China caused by a novel mutation in the intrinsic factor gene—a case report
por: Ruan, Jing, et al.
Publicado: (2020)

S184: SAFETY AND OUTCOMES FOLLOWING IMMUNOSUPPRESSIVE THERAPY WITH ATG/CYCLOSPORIN +/- ELTROMBOPAG FOR OLDER PATIENTS WITH SEVERE APLASTIC ANEMIA
por: Prabahran, Ashvind, et al.
Publicado: (2023)

An investigation of long-term outcome of rabbit anti-thymocyte globulin and cyclosporine therapy for pediatric severe aplastic anemia
por: Chang, Lixian, et al.
Publicado: (2023)

Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series
por: Martynova, Anastasia, et al.
Publicado: (2021)

PB2049: THE EFFICACY OF HETROMBOPAG PLUS CYCLOSPORINE A IN PATIENTS WITH TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA: A PROSPECTIVE REGISTRY STUDY
por: Gong, Yuemin, et al.
Publicado: (2023)

The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia
por: Işık, Ayşe, et al.
Publicado: (2013)

PB1950: MASS CYTOMETRY ANALYSIS IDENTIFIES T CELL IMMUNE SIGNATURE FOR APLASTIC ANEMIA AND PREDICTS RESPONSE TO CYCLOSPORINE
por: Zhang, L., et al.
Publicado: (2022)

Aplastic Anemia in China
por: Liu, Chunyan, et al.
Publicado: (2018)

Calcineurin Inhibitors and Neutropenia: Is Cyclosporine Superior to Tacrolimus?
por: Duggal, Tanu, et al.
Publicado: (2019)

Fatal Epstein-Barr Virus Reactivation in an Acquired Aplastic Anemia Patient Treated with Rabbit Antithymocyte Globulin and Cyclosporine A
por: Takahashi, Tohru, et al.
Publicado: (2015)

Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan
por: Imada, Kazunori, et al.
Publicado: (2020)

P761: UMBILICAL CORD BLOOD ORIGIN CELLS RECONSTRUCT THE HEMATOPOIESIS OF APLASTIC ANEMIA ANIMAL MODEL
por: Chen, Zesong, et al.
Publicado: (2023)

Gingival enlargement due to Cyclosporine A therapy in aplastic anaemia
por: Sabnis, Girish R., et al.
Publicado: (2011)

Severe Aplastic Anemia Presenting as Neutropenic Sepsis
por: Daniels, Natasha Faye, et al.
Publicado: (2020)

COVID-19 in children with severe aplastic anemia
por: Thakkar, Dhwanee, et al.
Publicado: (2022)

Massive eosinophilia despite severe aplastic anemia
por: Takahashi, Aya, et al.
Publicado: (2022)

Idiopathic Aplastic Anemia: An Update
por: Solomou, Elena E.
Publicado: (2019)

Gut inflammation in the pathogenesis of acquired aplastic anemia
por: Zhao, Xi-Chen, et al.
Publicado: (2020)

Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia
por: Contejean, Adrien, et al.
Publicado: (2019)

Sirolimus versus cyclosporine A in patients with primary acquired pure red cell aplasia: a prospective cohort study
por: Yang, Yuan, et al.
Publicado: (2023)

Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study
por: Yang, Wenrui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1oq5qghih9rn58kndedcjo5p20